Recruiting
Epilepsy
RecruitingInvestigational
Phase 2 Study Evaluating OV329 on Photo‑Induced EEG Response in Adults with Epilepsy
Investigational
- Substances:–
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
18 trials match your criteria
Recruiting
Epilepsy
RecruitingInvestigationalNo placebo
[18F]CPFPX PET in Patients With Drug-Resistant Epilepsy and Healthy Subjects
InvestigationalNo placebo
- Substances:[18F]CPFPX
Countries:
France
France- Participants:18–64 years · Healthy volunteers
- Substances:[18F]CPFPX
Recruiting
Epilepsy+1
RecruitingRegistered drug
Study on the Safety and Effectiveness of Sirolimus and Vigabatrin for Preventing Symptoms in Infants with Tuberous Sclerosis Complex
Registered drug
- Substances:SirolimusVigabatrin
Countries:
Poland
Poland- Participants:0–17 years
- Substances:Sirolimus
Recruiting
Epilepsy+1
RecruitingRegistered drug
Study on the Effectiveness and Safety of Sirolimus for Patients with Drug-Resistant Epilepsy Linked to Tuberous Sclerosis Complex
Registered drug
- Substances:Sirolimus
Countries:Poland
Poland- Participants:0–17 years · 18–64 years
- Substances:Sirolimus
Recruiting
Epilepsy
RecruitingInvestigational
Study on Cannabidiol and Dronabinol for Children with Refractory Epilepsy
Investigational
- Substances:CannabidiolDronabinol
Countries:The Netherlands
The Netherlands- Participants:0–17 years
- Substances:Cannabidiol
Recruiting
Epilepsy
RecruitingInvestigationalNo placebo
Study on Clioquinol for Reducing Seizures in Patients with Drug-Resistant Epilepsy
InvestigationalNo placebo
- Substances:Clioquinol
Countries:
Belgium
Belgium- Participants:0–17 years · 18–64 years
- Substances:Clioquinol
Not yet recruiting
Epilepsy
Not yet recruitingRegistered drug
Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy
Registered drug
- Substances:Fluoxetine
Countries:France
France- Participants:0–17 years
- Substances:Fluoxetine
Not yet recruiting
Epilepsy
Not yet recruitingInvestigationalNo placebo
Long‑Term Safety and Tolerability of Probenecid (PTI5803) as Adjunctive Therapy in Patients ≥14 Years with Drug‑Resistant Focal Epilepsy due to Focal Cortical Dysplasia
InvestigationalNo placebo
- Substances:–
Countries:France
France- Participants:0–17 years · 18–64 years
Not yet recruiting
Epilepsy
Not yet recruitingInvestigationalNo placebo
Safety and Tolerability of PTI5803 in Patients Aged 14 Years and Older With Drug‑Resistant Seizures Due to Focal Cortical Dysplasia
InvestigationalNo placebo
- Substances:–
Countries:France
France- Participants:0–17 years · 18–64 years
Not recruiting
Epilepsy
Not recruitingInvestigational
A study of TRV045 to test its effects on brain cell electrical activity in healthy adult men for epilepsy treatment development
Investigational
- Substances:TRV045
Countries:The Netherlands
The Netherlands- Participants:18–64 years · Healthy volunteers
- Substances:TRV045
Not recruiting
Epilepsy
Not recruitingInvestigationalNo placebo
Evaluation of 18F-DPA-714 PET-MRI imaging for locating epileptic focus in patients with drug-resistant partial epilepsy before surgery
InvestigationalNo placebo
- Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
Countries:France
France- Participants:0–17 years · 18–64 years · Healthy volunteers
- Substances:N,N-Diethyl-2-(2-(4-(2[(18)F]-Fluoroethoxy)Phenyl)5,7Dimethylpyrazolo[1,5A]Pyrimidin-3-Yl)Acetamide
Not recruiting
Epilepsy+1
Not recruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of Sirolimus for Treating Drug-Resistant Epilepsy in Children with Rare Brain Disorders Linked to mTOR Pathway Activation
Registered drugNo placebo
- Substances:Sirolimus
Countries:Poland
Poland- Participants:0–17 years
- Substances:Sirolimus